HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Santamaría, C. Articles by Gonzalez, M. Search for Related Content PubMed PubMed Citation Articles by Santamaría, C. Articles by Gonzalez, M.

The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia

¹ Hospital Universitario, Salamanca
² Centro de Investigación del Cáncer-IBMCC (USAL-CSIC) of Salamanca
³ Complejo Hospitalario de Leon
⁴ Hospital Central de Asturias, Oviedo
⁵ Hospital General de Segovia
⁶ Hospital Rìo Hortega, Valladolid, Spain
⁷ Hospital Miguel Servet, Zaragoza, Spain

Correspondence: Ramon Garcia-Sanz, MD, PhD, Department of Hematology, University Hospital of Salamanca, Paseo de san Vicente, 58-182, Salamanca 37007 Spain. E-mail:rgarcias{at}usal.es

Background: The gene for preferentially expressed antigen of melanoma (PRAME) has been shown to be over-expressed in acute promyelocytic leukemia, but its actual incidence and clinical impact are still unknown.

Design and Methods: We studied PRAME expression at diagnosis using real-time quantitative polymerase chain reaction in 125 patients with acute promyelocytic leukemia enrolled in the Spanish PETHEMA-96 (n=45) and PETHEMA-99 (n=80) clinical trials. In addition, PRAME expression was evaluated as a marker of disease activity in 225 follow-up samples from 67 patients with acute promyelocytic leukemia.

Results: At diagnosis, PRAME expression in patients with acute promyelocytic leukemia was significantly higher (p<0.001) than in patients with non-M3 acute myeloid leukemia (n=213) and in healthy controls (n=10). Furthermore, patients with acute promyelocytic leukemia with high PRAME expression had a favorable outcome. Thus, the 5-year relapse-free survival was better in patients with >100-fold PRAME expression (86% vs. 74%; p=0.03), and this cut-off established two sub-groups with different relapse-free survival rates among patients with a white cell count <10⁹/L (5-year relapse-free survival 94% vs. 80%, p=0.01). This effect was similar in patients with a white cell count >10⁹/L, although differences were not statistically significant. In multivariate analysis, white cell count >10⁹/L (p<0.001), bone marrow blasts >90% (p=0.001), and PRAME expression <100-fold (p=0.009) were associated with short relapse-free survival. Samples at remission showed PRAME levels similar to those in normal controls while samples at relapse over-expressed PRAME again. Furthermore, 12/13 samples collected within the 6-month period preceding relapse showed a >10-fold increase in PRAME expression levels.

Conclusions: Low PRAME expression defines a subgroup of patients with acute promyelocytic leukemia with a short relapse-free survival. This marker could be useful as a secondary marker for monitoring patients with acute promyelocytic leukemia.

Key words: acute promyelocytic leukemia, PRAME, real-time quantitative PCR.

This article has been cited by other articles:

				C. M. Santamaria, M. C. Chillon, R. Garcia-Sanz, C. Perez, M. D. Caballero, F. Ramos, A. G. de Coca, J. M. Alonso, P. Giraldo, T. Bernal, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia Blood, July 2, 2009; 114(1): 148 - 152. [Abstract] [Full Text] [PDF]